Clinical Trial

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Protocol Amendment History 2 changes
notable Trial sites expanded: 194 -> 202 locations 2026-07-08
notable Trial sites expanded: 190 -> 194 locations 2026-04-21
Trial Details
NCT Number NCT06338995
Lead Sponsor Eli Lilly and Company
Conditions Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment 510 participants
Start Date 2024-04-29
Primary Completion 2027-05 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-20